NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
NI‐0801 is a fully human monoclonal antibody against chemokine (C‐X‐C motif) ligand 10 (CXCL10), which is involved in the recruitment of inflammatory T cells into the liver. The safety and efficacy of NI‐0801 was assessed in patients with primary biliary cholangitis. In this open‐label phase 2a study, patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid received six consecutive intravenous administrations of NI‐0801 (10 mg/kg) every 2 weeks. Patients were followed up for 3 months after the last infusion. Liver function tests, safety assessments, as well as pharmacokinetic and pharmacodynamic parameters were evaluated at different time points throughout the dosing period and the safety follow‐up period. Twenty‐nine patients were enrolled in the study and were treated with NI‐0801. The most frequently reported adverse events included headaches (52%), pruritus (34%), fatigue (24%), and diarrhea (21%). No study drug‐related serious adverse events were reported. NI‐0801 administration did not lead to a significant reduction in any of the liver function tests assessed at the end of the treatment period (i.e., 2 weeks after final NI‐0801 administration) compared to baseline. Conclusion: Despite clear pharmacologic responses in the blood, no therapeutic benefit of multiple administrations of NI‐0801 could be demonstrated. The high production rate of CXCL10 makes it difficult to achieve drug levels that lead to sustained neutralization of the chemokine, thus limiting its targetability. (Hepatology Communications 2018;2:492‐503)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationKaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Fatigue in primary biliary cirrhosis
Cauch-Dudek, K., Abbey, S., Stewart, D. E., & Heathcote, E. J. (1998) · Gut · doi:10.1136/gut.43.5.705 · Cited by 237
Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis
Corpechot, C., Chrétien, Y., Chazouillères, O., & Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.019 · Cited by 235
Pruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225 · cited 2×
“, pruritus and fatigue,((21-24)) or symptoms associated with UDCA therapy, e.”
BackgroundCurbishley, S. M., Eksteen, B., Gladue, R. P., Lalor, P., & Adams, D. H. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62060-3 · Cited by 141
Self-citationInterpreting serological tests in diagnosing autoimmune liver diseases
Invernizzi, P., Lleo, A., & Podda, M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-979469 · Cited by 107
Self-citationChanging nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’
Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.031 · Cited by 97
Self-citationAn increased risk of urinary tract infection precedes development of primary biliary cirrhosis
Varyani, F. K., West, J., & Card, T. R. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-95 · Cited by 47 · cited 12×
“Given the possible insufficient neutralization of the target in the tissue, the current study does not provide a clear answer regarding the potential role of CXCL10 in the pathogenesis of PBC.”
ResultInfluential
Cited by
Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523
Self-citationLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Tanaka, A., Hirohara, J., Nakano, T., Matsumoto, K., Chazouillères, O., Takikawa, H., Hansen, B. E., Carrat, F., & Corpechot, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.010 · Cited by 148
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationThe Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology · doi:10.1002/hep.32011 · Cited by 45
Self-citation
Metadata
- Authors
- de Graaf, K. L., Lapeyre, G., Guilhot, F., Ferlin, W., Curbishley, S. M., Carbone, M., Richardson, P., Moreea, S., McCune, C. A., Ryder, S. D., Chapman, R. W., Floreani, A., Jones, D. E., de Min, C., Adams, D. H., & Invernizzi, P.
- Venue
- Hepatology Communications
- Published
- 2018-03-23
- Volume
- 2
- Issue
- 5
- Pages
- 492-503
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2790210268
- Cited by
- 48
- References
- 11
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. https://app.cochat.ai/papers/10.1002/hep4.1170
- The paper
- de Graaf, K. L., Lapeyre, G., Guilhot, F., Ferlin, W., Curbishley, S. M., Carbone, M., Richardson, P., Moreea, S., McCune, C. A., Ryder, S. D., Chapman, R. W., Floreani, A., Jones, D. E., de Min, C., Adams, D. H., & Invernizzi, P. (2018). NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatology Communications. https://doi.org/10.1002/hep4.1170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.